Eli Lilly vet takes helm at Brickell Biotech; Stemline’s Elzonris secures speedy EU review

Brickell Biotech has hired industry veteran and Lilly $LLY Chief Marketing Officer Robert Brown to take over the reins at the dermatology company as it preps a late-stage trial evaluating its drug, sofpironium bromide, in patients with excessive underarm sweating in the first half of 2019. Brown, who has spent over three decades at Lilly, is set to replace Brickell’s current CEO and co-founder Reginald Hardy on January 1.

Oncology-focused drug developer Stemline Therapeutics $STML has won accelerated review from the EU health regulator for its drug Elzonris for use in blastic plasmacytoid dendritic cell neoplasm (BPDCN) – a historically rare, aggressive disease for which there are no approved or standard therapies. “There was uncertainty as to whether the US data (single arm trial in frontline patients) would also support an EU approval, and today’s update clearly answers this question,” Cowen analysts wrote in a note on Tuesday. The announcement follows FDA’s decision to grant priority review for Elzonris for the same indication – the agency is expected to make its decision by February 21, 2019.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->